Karyopharm Therapeutics Inc.KPTINASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-7.8%
5Y CAGR-3.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-7.8%/yr
vs +8.8%/yr prior
5Y CAGR
-3.6%/yr
Recent deceleration
Acceleration
-16.5pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $230.82M | -10.8% |
| 2024 | $258.67M | -4.4% |
| 2023 | $270.63M | -8.0% |
| 2022 | $294.06M | -3.5% |
| 2021 | $304.69M | +9.9% |
| 2020 | $277.23M | +21.7% |
| 2019 | $227.76M | +8.3% |
| 2018 | $210.22M | +59.1% |
| 2017 | $132.14M | +19.2% |
| 2016 | $110.89M | - |